血嗜酸性粒细胞指导的哮喘急性发作住院患者全身糖皮质激素疗程:一项随机对照开放标签非劣效试验
本开放标签两中心随机试验纳入110例因哮喘急性发作住院的成人,比较常规5天泼尼松龙与基于血嗜酸性粒细胞的指导治疗(嗜酸性粒细胞<300 cells/µL用3天,≥300 cells/µL用5天)。治疗失败率分别为10.9%和7.3%,绝对差3.6%(95%CI -8.9%至16.2%),符合非劣效。非嗜酸性粒细胞组在指导治疗下累积激素剂量显著低于嗜酸性粒细胞组(136 vs 214 mg;p=0.0004)。
要点
- 嗜酸性粒细胞指导治疗在哮喘急性发作住院成人中非劣效于常规5天激素。
- 非嗜酸性粒细胞亚组在指导治疗下累积激素剂量显著降低。
- 住院时长、哮喘控制问卷-5变化及14天内追加激素等无显著差异。
核心结论
- 在该概念验证试验中,嗜酸性粒细胞指导治疗安全减少了非嗜酸性粒细胞急性发作的全身激素暴露,同时维持非劣效结局。
研究设计与样本
- 开放标签、两中心随机对照非劣效试验,纳入110例因哮喘急性发作住院的成人,1:1分配至常规治疗(5天泼尼松龙)或嗜酸性粒细胞指导治疗。
主要发现
- 治疗失败率在嗜酸性粒细胞指导组为6/55(10.9%),常规治疗组为4/55(7.3%),绝对差3.6%(95%CI -8.9%至16.2%),符合非劣效。
- 嗜酸性粒细胞指导组中,非嗜酸性粒细胞发作累积激素剂量显著低于嗜酸性粒细胞发作(136 vs 214 mg;p=0.0004),常规治疗组无此差异(186 vs 211 mg;p=0.18)。
- 住院时长、哮喘控制问卷-5变化、14天内追加激素 bursts 及至1年下次发作时间均无显著差异。
关键数值与推荐
- 嗜酸性粒细胞指导治疗:激素前血嗜酸性粒细胞<300 cells/µL用3天泼尼松龙,≥300 cells/µL用5天。
- 主要结局非劣效界值为20%。
临床怎么用
- 对住院哮喘急性发作成人,可依据激素前血嗜酸性粒细胞计数(<300 cells/µL)将全身激素疗程缩短至3天。
局限性
- 开放标签设计、样本量较小(110例)、两中心,为概念验证试验,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic corticosteroids for 5-7 days are standard care for asthma exacerbations, but the optimal duration and potential for precision prescribing remain unclear. Biomarker-guided approaches could reduce corticosteroid exposure without compromising outcomes. We aimed to evaluate whether the blood eosinophil count can be used to safely reduce systemic corticosteroid exposure in hospitalised asthma exacerbations. METHODS: In this open-label, two-centre randomised trial, adults hospitalised for asthma exacerbation were assigned 1:1 to usual care (5 days prednisolone) or eosinophil-guided care using blood eosinophil counts obtained prior to corticosteroid administration (3 days if eosinophils <300 cells/µL; 5 days if ≥300 cells/µL). The primary outcome was non-inferiority of treatment failure rates (composite of extension of steroid duration, mechanical ventilation or death), with a prespecified 20% non-inferiority margin. RESULTS: Among 110 randomised patients (55 per group), 60% were eosinophilic, and 40% non-eosinophilic. Treatment failure occurred in 6/55 (10.9%) of eosinophil-guided versus 4/55 (7.3%) of usual care patients, with a 3.6% absolute difference (95% CI -8.9% to 16.2%), meeting non-inferiority. Cumulative corticosteroid dose per patient was similar between groups but significantly lower for non-eosinophilic than eosinophilic exacerbations in the eosinophil-guided group (136 vs 214 mg; p=0.0004), a difference not observed in usual care (186 vs 211 mg; p=0.18). Length of stay, Asthma Control Questionnaire-5 change, additional steroid bursts at 14 days or time to next exacerbation up to 1 year showed no significant differences. CONCLUSION: Eosinophil-guided therapy safely reduced systemic corticosteroid exposure in non-eosinophilic exacerbations while maintaining non-inferior outcomes in this proof-of-concept trial. TRIAL REGISTRATION NUMBER: NCT05417906.
引用
- Yii, Tay, Lee, et al. Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial. Thorax. 2026. PMID: 41339088. doi:10.1136/thorax-2025-223961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。